Collectively, these analysis results demonstrated that for the NSCLC patients in an advanced stage, low expression of FAP and first-line immunotherapy might be factors predicting better efficacy of PD-1 blockade therapy. This evidence concerns the gene FAP and non-small cell lung carcinoma.